Intrapleural Minocycline After Aspiration of Spontaneous Pneumothorax
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The estimated recurrence rate of primary spontaneous pneumothorax is 23-50% after the first episode, and the optimal treatment remains unknown. In the recently published British Thoracic Society (BTS) guidelines, simple aspiration is recommended as first line treatment for all primary pneumothoraces requiring intervention. However, the 1 year recurrence rate of this procedure was as high as 25-30%, making it inappropriate as a standard of care.
Intrapleural instillation of a chemical irritant (chemical pleurodesis) is an effective way to shorten the duration of air leaks and reduce the rates of recurrent spontaneous pneumothorax in surgical and non-surgical patients. Many chemical irritants (tetracycline, talc, and minocycline) have been used to decrease the rate of recurrence in spontaneous pneumothorax. Tetracycline, which was the most commonly used irritant, is no longer available. Talc insufflation of the pleural cavity is safe and effective for primary spontaneous pneumothorax. However, it should be applied either with surgical or medical thoracoscopy. Minocycline, a derivative of tetracycline, is as effective as tetracycline in inducing pleural fibrosis in rabbits. In the previous studies, we have shown that additional minocycline pleurodesis is a safe and convenient procedure to decrease the rates of ipsilateral recurrence after thoracoscopic treatment of primary spontaneous pneumothorax. In the present study, additional minocycline pleurodesis will be randomly administered in patients with first episode of primary spontaneous pneumothorax after simple aspiration. The primary goal is to test if intrapleural minocycline can reduce the rate of recurrence. The secondary goals are to evaluate the safety profile, short-term results, and long-term effects of minocycline pleurodesis after simple aspiration. The sites of study include National Taiwan University Hospital and Far Eastern Memorial Hospital. A total of 300 patients (150 patients in each arm) will be included for this study.
| Condition | Intervention |
|---|---|
|
Pneumothorax |
Procedure: Intrapleural Minocycline application |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Prevention |
| Official Title: | Intrapleural Minocycline After Manual Aspiration for the Prevention of Primary Spontaneous Pneumothorax. A Phase III Multicenter Prospective Randomized Controlled Trial |
Eligibility| Ages Eligible for Study: | 15 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 15-50years old
- primary pneumothorax first attack
- viceral pleura to chest wall more then 2 cm on CXR
Exclusion Criteria:
- the lungs unable to expad fully after aspiration
- continuous leakage of air through chest tubes
- status complicated with hemothorax
- status post previous chest surgery or pleurodesis
- patient unwilling to accept the trial
Contacts and Locations| Contact: Kuang-Chau Tsai, Master | 886-2-89667000 ext 1125 | hikali@mail.femh.org.tw |
| Taiwan | |
| Far Eastern Memorial Hospital | Recruiting |
| Pan-Chiao, Taipei county, Taiwan | |
| Contact: Kuang-Chau Tsai, Master 886-2-89667000 ext 1125 hikali@mail.femh.org.tw | |
| Study Chair: | YC Lee, PhD | National Taiwan University Hospital |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00839553 History of Changes |
| Other Study ID Numbers: | 95042 |
| Study First Received: | February 6, 2009 |
| Last Updated: | February 6, 2009 |
| Health Authority: | Taiwan: Department of Health |
Additional relevant MeSH terms:
|
Pneumothorax Pleural Diseases Respiratory Tract Diseases Minocycline |
Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013